Australian Pine, IgE, Serum
Use
The test is useful for establishing a diagnosis of an allergy to the Australian pine, defining the allergen responsible for eliciting signs and symptoms, and identifying allergens that are responsible for allergic responses or anaphylactic episodes. It confirms sensitization prior to beginning immunotherapy and investigates the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens. Testing for IgE antibodies is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists or in patients where medical management does not depend upon identification of allergen specificity.
Special Instructions
Not provided.
Limitations
Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum, and test results must be interpreted in the clinical context. Additionally, false-positive results for IgE antibodies may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases.
FDA ApprovedNew York Approved
Methodology
Immunoassay (FEIA)
Biomarkers
Australian Pine IgE
Protein
LOINC Codes
- 6032-7 - Australian pine IgE Qn
- 6032-7 - Australian pine IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL for every 5 allergens requested
Minimum Volume
0.3 mL for 1 allergen
Container
Preferred: Serum gel; Acceptable: Red top
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis: OK; Gross lipemia: OK
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |